For adults in the United Kingdom, sight is the most valuable sense, a cross-sectional web-based survey found.Jamie Enoch, MSc, and colleagues collected responses from March 2016 to April 2016 from 250 U.K. adults aged 22 to 80 years. Participants were …
Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will releas…
HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy
The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology…
Device Detects Opioid Overdose, Arouses Patients Out of Respiratory Arrest
Med-botics, a firm based in Colorado Springs, won FDA Breakthrough Device status for its Oxalert EPO (Enhanced Pulse Oximeter), a device developed to prevent respiratory arrest from opioid overdoses. Post-op patients and others on heavy opioid therapy can stop breathing, which can lead to death if not monitored carefully. The Oxalert EPO monitors p (Read more...)
VIDEO: Eyenovia building ‘robust pipeline’
SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Sean Ianchulev, MD, MPH, the CEO of Eyenovia, discusses some of the recent progress the company has made on upcoming trials and methods.
Teprotumumab Improves Bulging, QOL in Thyroid Eye Disease
The pooled results of phase 2 and 3 clinical trials could pave the way for first approved drug for thyroid eye disease. Medscape Medical News